Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat

American Journal of Physiology - Renal Physiology

Volumn 287, Issue 1 56-1, 2004, Pages

  Erdely, Aaron ^a,c   Freshour, Gary ^a   Smith, Cheryl ^a   Engels, Kevin ^a   Olson, Jean L ^b   Baylis, Chris ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Glomerular filtration rate; Nitric oxide deficiency; Proteinuria

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PUROMYCIN AMINONUCLEOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; KIDNEY INJURY; KIDNEY MEDULLA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; RAT; RENAL PROTECTION;

EID: 2942672912     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00349.2003     Document Type: Article

References (46)

1. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Corna D, Zoja C, Cavallotti D, and Remuzzi G. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 52: 171-181, 1997.
2. Anderson S, Diamond JR, Karnovsky MJ, and Brenner BM. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82: 1757-1768, 1988.
3. Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, Schwartz D, Cabili S, Silverberg D, and Iaina A. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 47: 1515-1521, 1995.
4. Baylis C. Nitric oxide deficiency: both consequence and cause of chronic renal disease (CRD). Hypertension and Nephrology 5: 193-201, 2001.
5. Brenner BM and Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl 63: S124-S127, 1997.
6. Colasanti M, Persichini T, Meneqazzi M, Mariotto S, Giordano E, Caldarera CM, Soqos V, Lauro GM, and Suzuki H. Induction of nitric oxide synthase mRNA expression. Suppression by exogenous nitric oxide. J Biol Chem 270: 26731-26733, 1995.
7. De Alba J, Cardenas A, Moro MA, Leza JC, Lorenzo P, Bosca L, and Lizasoain I. Downregulation of neuronal nitric oxide synthase by nitric oxide after oxygen-glucose deprivation in rat forebrain slices. J Neurochem 72: 248-254, 1999.
8. Diamond JR and Karnovsky MJ. Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 122: 481-487, 1986.
9. Erdely A, Freshour G, Maddox D, and Baylis C. Decreased renal nitric oxide synthase (NOS) with advanced type 2 diabetic nephropathy (DN) (Abstract). FASEB Late breaking (LB): 107, 2002.
10. Erdely A, Greenfeld Z, Wagner L, and Baylis C. Sexual dimorphism in the aging kidney: effects on injury and nitric oxide system. Kidney Int 63: 1021-1026, 2003.
11. Erdely A, Wagner L, Muller V, Szabo A, and Baylis C. Protection of Wistar-Furth rat from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 14: 2526-2533, 2003.
12. Fitzgibbon WR, Greene EL, Grewal JS, Hutchison FN, Self SE, Latten SY, and Ullian ME. Resistance to remnant nephropathy in the Wistar-Furth rat. J Am Soc Nephrol 10: 814-821, 1999.
13. Fogo A. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 23: 161-171, 2003.
14. Fogo A, Yoshida Y, Glick AD, Homma T, and Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82: 322-330, 1988.
15. Fujihara CK, De Nucci G, and Zatz R. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 5: 1498-1507, 1995.
16. Fujihara CK, Mattar AL, Vieira JM Jr, Malheiros DM, Noronha Id Ide L, Goncalves AR, De Nucci G, and Zatz R. Evidence for the existence of two distinct functions for the inducible NO synthase in the rat kidney: effect of aminoguanidine in rats with 5/6 ablation. J Am Soc Nephrol 13: 2278-2287, 2002.
17. Glasser RJ, Velosa JA, and Michael AF. Experimental model of sclerosis. 1. Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest 36: 519-526, 1977.
18. Grond J, Beukers JY, Schilthuis MS, Weening JJ, and Elema JD. Analysis of renal structural and functional features in two rat strains with a different susceptibility to glomerular sclerosis. Lab Invest 54: 77-83, 1986.
19. Grond J, Muller EW, van Goor H, Weening JJ, and Elema JD. Differences in puromycin aminonucleoside nephrosis in two rat strains. Kidney Int 33: 524-529, 1988.
20. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, and Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol Renal Fluid Electrolyte Physiol 241: F85-F93, 1981.
21. Kang DH, Nakagawa T, Feng L, and Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002.
22. Katoh T, Takahashi K, Klahr S, Reyes AA, and Badr KF. Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol 4: 1690-1694, 1994.
23. Kone BC, Kuncewicz T, Zhang W, and Yu ZY. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol 285: F178-F190, 2003.
24. Lau KS, Grange RW, Chang WJ, Kamm KE, Sarelius I, and Stull JT. Skeletal muscle contractions stimulate cGMP formation and attenuate vascular smooth muscle myosin phosphorylation via nitric oxide. FEBS Lett 431: 71-74, 1998.
25. ΔΔCt method. Methods 25: 402-408, 2001.
26. Mattson DL and Bellehumeur TG. Neural nitric oxide synthase in the renal medulla and blood pressure regulation. Hypertension 28: 297-303, 1996.
27. Muller V, Engels K, and Baylis C. Chronic inhibition of nitric oxide synthase (NOS) renders the C57BL6 mouse susceptible to the development of chronic renal disease (Abstract). J Am Soc Nephrol 14: 625A, 2003.
28. Ni Z and Vaziri ND. Downregulation of nitric oxide synthase in nephrotic syndrome: role of proteinuria. Biochim Biophys Acta 1638: 129-137, 2003.
29. Ollerstam A, Pittner J, Persson AE, and Thorup C. Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase. J Clin Invest 99: 2212-2218, 1997.
30. Ren YL, Garvin JL, Ito S, and Carretero OA. Role of neuronal nitric oxide synthase in the macula densa. Kidney Int 60: 1676-1683, 2001.
31. Roczniak A, Fryer JN, Levine DZ, and Burns KD. Downregulation of neuronal nitric oxide synthase in the rat remnant kidney. J Am Soc Nephrol 10: 704-713, 1999.
32. Schmidt R, Domico J, Samsell L, Yokota S, Tracy T, Sorkin M, Engels K, and Baylis C. Indices of activity of the nitric oxide system in patients on hemodialysis. Am J Kidney Dis 34: 228-234, 1999.
33. Schmidt RJ and Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58: 1261-1266, 2000.
34. Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, and Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol Renal Physiol 276: F794-F797, 1999.
35. NOXV) do not predict renal vascular NO production. Kidney Int 48: 1272-1277, 1995.
36. Szabo AJ, Wagner L, Erdely A, Lau K, and Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 64: 1765-1771, 2003.
37. Ullian ME, Islam MM, Robinson CJ, Fitzgibbon WR, Tobin ET, and Paul RV. Resistance to mineralocorticoids in Wistar-Furth rats. Am J Physiol Heart Circ Physiol 272: H1454-H1461, 1997.
38. Vallon V, Traynor T, Barajas L, Huang YG, Briggs JP, and Schnermann J. Feedback control of glomerular vascular tone in neuronal nitric oxide synthase knockout mice. J Am Soc Nephrol 12: 1599-1606, 2001.
39. Vaziri ND, Ni Z, Wang XQ, Oveisi F, and Zhou XJ. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol Renal Physiol 274: F642-F649, 1998.
40. Wagner L, Riggleman A, Erdely A, Couser W, and Baylis C. Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 62: 532-536, 2002.
41. Walker LM, Shah SV, and Mayeux PR. Lack of a role for inducible nitric oxide synthase in an experimental model of nephrotic syndrome. Biochem Pharmacol 60: 137-143, 2000.
42. Welch WJ, Wilcox CS, and Thomson SC. Nitric oxide and tubuloglomerular feedback. Semin Nephrol 19: 251-262, 1999.
43. Xia Y, Dawson VL, Dawson TD, Solomon SH, and Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite mediated. Proc Natl Acad Sci USA 93: 6770-6774, 1996.
44. Xiao S, Erdely A, Wagner L, and Baylis C. Uremic levels of BUN do not cause nitric oxide deficiency in rats with normal renal function. Am J Physiol Renal Physiol 280: F996-F1000, 2001.
45. Zatz R and Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 32: 958-964, 1998.
46. Zheng Y, Shirato I, Maeda A, Kobayashi N, Liao J, Shou I, Fukui M, and Tomino Y. Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis. J Nephrol 15: 36-41, 2002.